BioWorld

Jan. 24, 2006

Syntonix, Biovitrum In Deal On Long-Acting Clotting Product

Syntonix Pharmaceuticals Inc. agreed to out-license overseas rights to FIX:Fc, its preclinical recombinant Factor IX product for hemophilia B, to Biovitrum AB. (BioWorld Today) Read More

Tanox Earns Xolair Milestone; Peanut Allergy Work In Limbo

Studying Antibiotic Resistance In Soil, Scientists Hit Pay Dirt

Young Firm Novelix Growing Portfolio Via USC In-Licensing

Other News To Note

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...